About
Voxeleron delivers AI-powered ophthalmic image analysis and clinical trial data management tailored for the life sciences industry. Designed for contract research organizations (CROs), reading centers, trial sponsors, and clinical sites, the platform enables teams to generate more accurate trial endpoints, streamline data sharing, and access insights in real time from any device. The company's flagship platform, iNebula, provides an intuitive interface for managing large ophthalmic imaging datasets across multiple study stakeholders. It supports device-agnostic OCT (optical coherence tomography) analysis, cross-platform standardization, and computer vision evaluations — making it easier to conduct consistent, reproducible analyses regardless of the imaging hardware in use. Voxeleron has been deployed in Phase 2 and Phase 3 clinical trials for conditions such as diabetic macular edema (DME) and rhegmatogenous retinal detachment (RRD). The platform's interoperability features accelerate trial timelines while maintaining compliance with stringent regulatory standards, including ISO 13485:2016 certification and SOC 2 compliance. In 2024, Voxeleron was acquired by Voiant, a leader in clinical trial imaging solutions, further expanding its capabilities and reach in ophthalmic drug development. The combined entity is positioned to support sponsors seeking faster, more reliable endpoints for breakthrough eye disease therapies. Voxeleron is best suited for enterprise life science organizations, ophthalmology-focused biotech companies, and imaging reading centers involved in regulated clinical research.
Key Features
- AI-Powered OCT Image Analysis: Leverages artificial intelligence and computer vision to analyze optical coherence tomography (OCT) images with high accuracy, supporting consistent endpoint generation across clinical trials.
- iNebula Clinical Data Platform: A centralized, intuitive interface for managing and sharing large ophthalmic imaging datasets among sponsors, CROs, reading centers, and clinical sites in real time.
- Device-Agnostic Imaging: Supports cross-platform standardization of ophthalmic images regardless of the OCT device used, enabling consistent data quality across multi-site trials.
- Real-Time Data Access: Provides stakeholders with on-demand access to imaging data and insights from any device or location, accelerating decision-making during trials.
- Regulatory Compliance & Certification: ISO 13485:2016 and SOC 2 certified, ensuring the platform meets stringent quality management and data security standards required for regulated clinical research.
Use Cases
- Managing and standardizing OCT imaging data across multiple sites in Phase 2 and Phase 3 ophthalmic clinical trials
- Generating accurate, reproducible endpoints for FDA and regulatory submissions in retinal disease drug development
- Sharing large ophthalmic image datasets in real time among sponsors, CROs, and reading centers during active trials
- Conducting cross-platform standardization and computer vision evaluations for device-agnostic trial imaging
- Performing post-hoc biomarker analysis and unique endpoint evaluation for conditions like diabetic macular edema and retinal detachment
Pros
- Deep Ophthalmology Specialization: Purpose-built for ophthalmic clinical trials, offering domain-specific AI analysis tools that general-purpose platforms cannot match.
- Device-Agnostic Interoperability: Works across different OCT imaging hardware, enabling multi-site trials to standardize data without being locked into a single device vendor.
- Regulatory-Grade Certifications: ISO 13485:2016 and SOC 2 certifications provide sponsors and CROs confidence in the platform's quality and data security posture.
- Proven in Real Trials: Documented use in Phase 2 and Phase 3 programs for conditions like DME and RRD, with published case studies from multiple pharma partners.
Cons
- Highly Niche Focus: Limited to ophthalmic clinical research, making it unsuitable for broader clinical trial management or non-ophthalmology therapeutic areas.
- Enterprise Pricing Only: No self-serve or transparent pricing model; the platform targets enterprise life science organizations with custom contracts.
- Limited Public Documentation: Scant publicly available technical documentation or feature walkthroughs, making independent evaluation difficult without direct engagement with the sales team.
Frequently Asked Questions
What is Voxeleron?
Voxeleron is an AI-powered platform for ophthalmic image analysis and clinical trial data management. It helps CROs, reading centers, trial sponsors, and clinical sites generate accurate endpoints and access imaging data in real time.
What is iNebula?
iNebula is Voxeleron's flagship clinical data platform, providing an intuitive interface for managing and sharing large ophthalmic imaging datasets across multiple stakeholders during clinical trials.
Who uses Voxeleron?
Voxeleron is used by contract research organizations (CROs), ophthalmic reading centers, pharmaceutical and biotech sponsors, and clinical sites conducting regulated eye disease trials.
Is Voxeleron certified for regulated clinical use?
Yes. Voxeleron holds ISO 13485:2016 certification for quality management systems in medical devices, as well as SOC 2 certification for data security and privacy.
What happened to Voxeleron?
Voxeleron was acquired by Voiant, a leader in clinical trial imaging solutions, to advance the development of innovative treatments for eye diseases and expand the platform's global reach.
